# Table of Contents

## Highlights of This Issue 4975

### SPECIAL FEATURES

#### Editorial

4977 AACR Cancer Progress Report 2014: Transforming Lives Through Research
Jesse Potash and Kenneth C. Anderson

#### Policy Statement

4978 Reliable and Effective Diagnostics Are Keys to Accelerating Personalized Cancer Medicine and Transforming Cancer Care: A Policy Statement from the American Association for Cancer Research
Charles L. Sawyers and Laura J. van ’t Veer

### CCR Translations

4982 The Future of Cancer Therapy: Selecting Patients Likely to Respond to PD1/L1 Blockade
Antoni Ribas and Paul C. Tumeh
See related article, p. 5064

### CCR New Strategies

4985 New Strategies in Acute Promyelocytic Leukemia: Moving to an Entirely Oral, Chemotherapy-Free Upfront Management Approach
Amer M. Zeidan and Steven D. Gore

### CCR Perspectives in Drug Approval

4994 FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation
Geoffrey Kim, Amy E. McKee, Yang-Min Ning, Maitreyyee Hazarika, Marc Theoret, John R. Johnson, Qiang Casey Xu, Shenghui Tang, Rajeshwari Sridhara, Xiaoping Jiang, Kun He, Donna Roscoe, W. David McGuinn, Whitney S. Helms, Anne Marie Russell, Sarah Pope Mikinski, Jeanne Fourie Zirkelbach, Justin Earp, Qi Liu, Amna Ibrahim, Robert Justice, and Richard Pazdur

## Molecular Pathways

5001 Molecular Pathways: Deregulation of Histone H3 Lysine 27 Methylation in Cancer—Different Paths, Same Destination
Teresa Ezponda and Jonathan D. Licht

## CANCER THERAPY: CLINICAL

5009 A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein–Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive Cancer

5023 Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma

5032 Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid Tumors
Toshio Shimizu, Patricia M. LoRusso, Kyri P. Papadopoulos, Amita Patnaik, Muralidhar Beeram, Lon S. Smith, Drew W. Rasco, Theresa A. Mays, Glenda Chambers, Anna Ma, Jing Wang, Robert Laliberte, Maurizio Voi, and Anthony W. Tolcher
Tumor Stromal Phenotypes Define VEGF Sensitivity—Response

Correction: A Severe Combined Immunodeficient–hu In Vivo Mouse Model of Human Primary Mantle Cell Lymphoma

ABOUT THE COVER
The cover shows acetylated histone H3 immunohistochemistry staining of skin biopsy at half an hour after the fifth doses of CUDC-101 treatment in the 275-mg/m² cohort. CUDC-101 induces the accumulation of acetylated histone H3. For details, see the article by Shimizu and colleagues on page 5032 of this issue.